Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Guillermo Garcia-Effron
exaly +8 more sources
Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique ...
David Perlin, Yanan Zhao
exaly +6 more sources
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy [PDF]
Pharmacology Research and Perspectives, 2019 Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half‐life allowing once ...
Voon Ong
exaly +4 more sources
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Microbiology Spectrum, 2023 Rezafungin is a novel once-weekly echinocandin for intravenous injection currently in development for the treatment of Candida infections and the prevention of Candida, Aspergillus, and Pneumocystis infections in allogeneic blood and marrow transplant ...
Voon Ong, Taylor Sandison
exaly +5 more sources
It’s Here, It’s There, There’s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis [PDF]
Infectious Diseases and TherapyRezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream.
Ryan Dare, Alina Viteri, J Myles Keck
exaly +3 more sources
In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris [PDF]
Journal of FungiObjectives: The aim of our study was to investigate the in vitro activity and in vivo efficacy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris isolates belonging to clade V.
Dávid Balázsi +8 more
doaj +3 more sources
Rezafungin as Primary Prophylaxis of Pneumocystis jirovecii Pneumonia in a Critically Ill Person Presenting with AIDS with Trimethoprim/Sulfamethoxazole Allergy: A Case Report [PDF]
Journal of FungiPrimary prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in people with HIV (PWH) and CD4+ counts
Martina Bottanelli +15 more
doaj +2 more sources
In Vitro Activity of Rezafungin Against Planktonic and Biofilm Forms of Candida albicans and Nakaseomyces glabratus Clinical Isolates from Vascular Infections in Poland: A Pilot Study [PDF]
PharmaceuticsBackground/Objectives: Certain yeast species are recognized as significant opportunistic pathogens, capable of causing severe systemic infections, particularly in immunocompromised individuals or those with disrupted physiological barriers.
Iwona Skiba-Kurek +6 more
doaj +2 more sources
Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient [PDF]
MicroorganismsPneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection predominantly affecting immunocompromised patients. Trimethoprim–sulfamethoxazole (TMP–SMX) remains the standard therapy but is often limited by severe toxicity ...
Rosario Fernández-Fernández +4 more
doaj +2 more sources
Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting [PDF]
Journal of Bone and Joint InfectionBone and joint infections secondary to Candida species are associated with high morbidity and mortality, requiring extended courses of antifungal therapy, with parenteral medications being first-line therapy. The reported use of antifungals in outpatient
A. J. Richards +8 more
doaj +2 more sources